AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

TOFACITINIB

10 registrations across 5 African markets— 7 active

Markets with TOFACITINIB

Recent registrations

Brand / ProductMarketHolderStatusExpires
TOFADOZ 5
TABLET, COATED; ORAL
🇿🇼ZimbabweMSN LABORATORIES LTDactiveNov 2030
TOFADOZ 10
TABLET, COATED; ORAL
🇿🇼ZimbabweMSN LABORATORIES LTDactiveNov 2030
Jitrit-5
Tablet
🇰🇪KenyaMicro Labs LimitedactiveAug 2030
TOFADOZ 5
Tablet
🇰🇪KenyaMSN Laboratories Private LimitedactiveJul 2030
Xeljanz 5 mg Tablets**
Tablet
🇳🇬NigeriaPfizer Specialties LtdactiveJan 2028
JITRIT-5
TABLET, COATED; ORAL
🇿🇼ZimbabweMICRO LABS LIMITEDactiveDec 2027
XELJANZ
TABLET; ORAL
🇿🇼ZimbabwePFIZER LABORATORIES (PTY) LTD, S.AactiveDec 2027
XELTIN 5MG TABLET
TABLET
🇲🇼MalawiexpiredMar 2025
TOFACITINIB NEAPOLIS
Comprimé pelliculé / 5 mg
🇹🇳TunisiaNEAPOLIS PHARMAexpiredJun 2022
XELJANZ
Comprimé pelliculé / 5 mg
🇹🇳TunisiaPF PRISM C.V C/O PFIZER NETHERLANDSexpiredNov 2018

TOFACITINIB in Africa — Regulatory Overview

TOFACITINIB is registered across 5 African markets with 10 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Zimbabwe, Kenya, Tunisia, Malawi and 1 more. AfricaRegulatory refreshes this data daily from official government sources.

Of the 10 registrations, 7 (70%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.